Form 4: 10x Genomics CEO Serge Saxonov Reports Acquisition of 171,428 Shares

Serge Saxonov, CEO of 10x Genomics, reports the acquisition of 171,428 shares of Class A Common Stock on March 17, 2025, along with details of beneficial ownership through various trusts.

Summary

• Serge Saxonov, the CEO of 10x Genomics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On March 17, 2025, Saxonov acquired 171,428 shares of Class A Common Stock in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs vest in equal quarterly installments over a three-year period, starting from February 21, 2025, contingent upon his continued service with the company.
• Following the reported transaction, Saxonov directly owns 1,092,968 shares of Class A Common Stock.
• He also indirectly owns shares through several trusts where he serves as trustee: the Andromeda Trust (27 shares), the Sirius Trust (870 shares), the Y/S Descendants' Trust (213,250 shares), and the Y/S Pot Trust (22,570 shares).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CEO acquiring more shares, even as part of a compensation package, generally signals confidence. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of RSUs by the CEO could be seen as a positive sign, indicating his confidence in the company's future performance.

Future Outlook

The vesting schedule of the RSUs indicates a commitment from the CEO for the next three years.

Industry Context

Tracking executive stock ownership is crucial for investors as it provides insights into management's alignment with shareholder interests. This filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Executive compensation packages often include stock options and RSUs to incentivize performance and align management's interests with those of shareholders.
• The vesting schedule of these RSUs is fairly standard, with quarterly vesting over a three-year period being a common practice.
• Comparing Saxonov's total equity ownership to that of CEOs at comparable genomics companies (e.g., Illumina, Pacific Biosciences) would provide a more comprehensive understanding of his stake in 10x Genomics.

Stakeholder Impact

• Shareholders may view the CEO's increased equity stake as a positive sign.
• Employees may see it as a sign of stability and confidence in the company's leadership.

Key Dates

Keywords

10x Genomics, TXG, Serge Saxonov, CEO, Form 4, Beneficial Ownership, Restricted Stock Units, RSUs, Class A Common Stock, Andromeda Trust, Sirius Trust, Y/S Descendants' Trust, Y/S Pot Trust